Treats benign prostatic hyperplasia. Sold as Uroxatral. Every FDA application for this active ingredient: 1 branded and 9 generic.
As of Nov 22, 2026, FDA lists 10 applications for Alfuzosin hydrochloride (sold as Uroxatral), first approved Jun 12, 2003, with 1 new use approved and 0 published complete response letters.
| Jun 12, 2003 | UroxatralNDA 21287 · New molecular entity | ADVANZ PHARMA | 14 | Marketed |
| Jul 18, 2011 | Alfuzosin HydrochlorideANDA 79013 | Apotex | 4 | Marketed |
| Jul 18, 2011 | Alfuzosin HydrochlorideANDA 79014 | PharmoBedient | 3 | Discontinued |
| Jul 18, 2011 | Alfuzosin HydrochlorideANDA 79054 | Torrent Pharmaceuticals | 7 | Discontinued |
| Jul 18, 2011 | Alfuzosin HydrochlorideANDA 79056 | Chartwell RX | 1 | Discontinued |
| Jul 18, 2011 | Alfuzosin HydrochlorideANDA 79057 | Sun Pharmaceutical Industries | 4 | Discontinued |
| Jan 17, 2012 | Alfuzosin HydrochlorideANDA 90284 | InvaGen Pharmaceuticals | 4 | Marketed |
| Aug 10, 2012 | Alfuzosin HydrochlorideANDA 90221 | Wockhardt Bio | 1 | Discontinued |
| Aug 30, 2012 | Alfuzosin HydrochlorideANDA 79060 | Aurobindo Pharma | 5 | Marketed |
| Jan 28, 2016 | Alfuzosin HydrochlorideANDA 203192 | Unichem Laboratories | 2 | Marketed |
| Alfuzosin HCl ER | Part D | $26.9M | +12% | 343,023 |
| Uroxatral | Part D | $1.6M | −7% | 210 |
Of the 5 whose ending is known, 0% met their primary endpoint, 40% missed it and 60% stopped early.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA